Open access · US-GOV
via ClinicalTrials.gov Clinical trial
IMPACT OF NIRMATRELVIR AND RITONAVIR (PAXLOVID®) ON MORTALITY, PROGRESSION TO SEVERE DISEASE, AND ACTIVITIES OF DAILY LIVING (ADL) WORSENING IN LONG-TERM CARE HOSPITALS (LTCHS) IN KOREA
Authors not listed
Pfizer · 2025
Abstract
The purpose of this study is to learn about the effects of the study medicine (called Paxlovid) for the possible treatment of COVID-19 in older adults who live in long-term care hospitals (LTCHs) in Korea. Researchers want to know whether Paxlovid lowers the chance of severe illness or death and helps people carry out their usual daily activities, remain free from aging and weakness, and maintain cognitive function.
This study is seeking participants who:
* are 60 years of age or older
* live in a long-term care hospital in Korea
* were diagnosed with COVID-19 on or after 14 January 2022, during the period when Paxlovid was available as part of routine care
* received Paxlovid within 5 days after their first COVID-19 symptoms (only for people in the Paxlovid group)
All participants in this study received their usual COVID-19 care. About half also received Paxlovid. Paxlovid was prescribed as part of routine care at the long-term care hospital, typically taken by mouth 2 times a day for 5 days.
The study team will compare the health results of people who received Paxlovid to those who did not, using similar parameters such as age, sex, and medical history. This will help the study team to understand whether Paxlovid makes a meaningful difference in stopping severe illness, death, or slow-down daily functioning.
Participants will not have any extra study visits or tests. The study team will only review information already recorded in their medical charts for up to 1 year after their COVID-19 symptom onset.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-31 MST
Cite this
APA
Anonymous. (2025). IMPACT OF NIRMATRELVIR AND RITONAVIR (PAXLOVID®) ON MORTALITY, PROGRESSION TO SEVERE DISEASE, AND ACTIVITIES OF DAILY LIVING (ADL) WORSENING IN LONG-TERM CARE HOSPITALS (LTCHS) IN KOREA. <em>Pfizer</em>. https://clinicaltrials.gov/study/NCT07089680
Vancouver
Anonymous. IMPACT OF NIRMATRELVIR AND RITONAVIR (PAXLOVID®) ON MORTALITY, PROGRESSION TO SEVERE DISEASE, AND ACTIVITIES OF DAILY LIVING (ADL) WORSENING IN LONG-TERM CARE HOSPITALS (LTCHS) IN KOREA. Pfizer. 2025.
BibTeX
@misc{anon2025IMPACT,
title = {IMPACT OF NIRMATRELVIR AND RITONAVIR (PAXLOVID®) ON MORTALITY, PROGRESSION TO SEVERE DISEASE, AND ACTIVITIES OF DAILY LIVING (ADL) WORSENING IN LONG-TERM CARE HOSPITALS (LTCHS) IN KOREA},
author = {Anonymous},
journal = {Pfizer},
year = {2025},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Trakya University 2026
Open access · US-GOV
Incremental Prognostic Value of Frailty Beyond the Nottingham Hip Fracture Score for Predicting 90-Day Mortality After Hip Fracture Surgery: A Prospective Cohort Study
National Eye Institute (NEI) 2012
Open access · US-GOV
NEI Intramural Biorepository for Retinal Diseases
University of Erlangen-Nürnberg Medical School 2020
Open access · US-GOV
Digital Dementia Registry Bavaria (digiDEM Bayern)
Tri-Service General Hospital (TSGH) 2025
Open access · US-GOV
Effectiveness of Precision Rehabilitative Exercise Training on Sarcopenia, Joint Range of Motion, Cognitive Function, Activities of Daily Living, Quality of Life, and Mood Status in Elderly Residents of Long-Term Care Facilities
Second Affiliated Hospital of Nanchang University 2006
Open access · US-GOV
Phenotypic Age Acceleration (PhenoAgeAccel) for Joint Prediction of Disease Risk, Mortality Risk, Life Expectancy, and Disease-Free Healthspan in Major Chronic Diseases
China National Center for Cardiovascular Diseases 2025
Open access · US-GOV